Quoin Pharmaceuticals Secures Orphan Drug Designation for QRX003
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a forward-thinking company dedicated to addressing rare diseases, has reached a significant milestone. The European Medicines Agency (EMA) has conferred Orphan Drug Designation for its flagship product, QRX003, aimed at treating Netherton Syndrome. This distinction not only highlights Quoin's commitment to innovation in therapeutics but also provides substantial advantages in the European market.
The Importance of Orphan Drug Designation
Orphan Drug Designation offers essential incentives to pharmaceutical companies focusing on rare diseases. Through this designation, Quoin can benefit from scientific advice regarding study protocols, reduced fees associated with drug development, and access to EU grants designed to support innovative treatments. Most importantly, if QRX003 receives approval, it will enjoy a decade of exclusivity in the European market, allowing Quoin to bring a much-needed therapy to patients suffering from this debilitating condition.
CEO Michael Myers on Progress
Quoin's CEO, Dr. Michael Myers, expressed enthusiasm regarding the company's ongoing clinical and regulatory advancements in the development of QRX003. He emphasized the encouraging clinical results obtained thus far, including notable improvements in skin healing and a significant reduction in severe itching, which are hallmark symptoms of Netherton Syndrome. Dr. Myers remarked, "This milestone marks an important step for Quoin and reinforces our commitment to patients in desperate need of effective therapies. Our trials continue to show promising efficacy and safety profiles, which underpin the potential of QRX003 as a broad-spectrum kallikrein inhibitor."
Ongoing Clinical Trials of QRX003
Currently, QRX003 is undergoing multiple late-stage clinical trials, designed to be a topical and non-systemic solution for Netherton Syndrome—a serious condition where existing treatment options are almost nonexistent. Quoin's innovative approach seeks to deliver a much-needed therapeutic option to patients and their families.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals is dedicated to developing and commercializing therapies aimed at rare and orphan diseases. The company's commitment is not only to innovation and research but also to meeting the unmet medical needs of patients worldwide. Quoin's pipeline includes four promising development products targeting various orphan conditions, such as Peeling Skin Syndrome, SAM Syndrome, and Scleroderma, among others. This diverse portfolio reflects Quoin’s strategic approach to creating solutions that matter most in the rare disease space.
Commitment to Communication
Quoin values transparent communication with stakeholders and the public. The company is dedicated to providing updates on the progress of QRX003 and its other developmental projects. For additional information, Quoin encourages interested parties to reach out via the provided contact details.
Frequently Asked Questions
What is Orphan Drug Designation?
Orphan Drug Designation is a status given to drugs intended for the treatment of rare diseases, providing various incentives and benefits during the development process.
How does QRX003 work?
QRX003 is designed as a topical treatment, functioning as a broad-spectrum kallikrein inhibitor to alleviate symptoms associated with Netherton Syndrome.
Who is Quoin Pharmaceuticals?
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company focusing on therapies for rare and orphan diseases, with a strong commitment to patient needs.
What other conditions does Quoin target?
In addition to Netherton Syndrome, Quoin aims to develop treatments for conditions like Peeling Skin Syndrome, SAM Syndrome, and Epidermolysis Bullosa.
How can I stay updated on Quoin's progress?
For updates, visit Quoin’s official website or contact their investor relations team for the latest information on their developments.
